GNOM
Global X Genomics & Biotechnology ETF
Price Chart
Latest Quote
$68.80
+2.46 (+3.72%)
Current Price
| Previous Close | $66.34 |
| Open | $66.46 |
| Day High | $68.98 |
| Day Low | $66.00 |
| Volume | 16,756 |
Fund Information
| Quarterly Dividend / Yield | N/A / 0.92% |
| Net Assets | $102.88M |
| Expense Ratio | 0.50% |
| Category | Health |
| Fund Family | Global X Funds |
| Net Asset Value | $66.52 |
| Premium/Discount | 3.43% |
| Quarterly Dividend Yield | 0.92% |
| Exchange | NGM |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $67.41 |
| SMA50 | $66.43 |
| SMA200 | $53.37 |
| RSI | 54.35 |
| ATR | 2.3410 |
| Rel Volume | 0.46 |
Performance History
| Week | +1.71% |
| Month | -2.13% |
| Quarter | +28.08% |
| 6 Months | +53.50% |
| YTD | +50.83% |
| Year | +59.61% |
| 3 Years | +90.36% |
| 5 Years | -19.53% |
| 10 Years | +13.77% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $68.80 | 16,756 |
| 2026-10-26 | $66.46 | 16,200 |
| 2026-10-23 | $65.58 | 15,300 |
| 2026-10-22 | $66.01 | 36,100 |
| 2026-10-21 | $68.72 | 14,500 |
| 2026-10-20 | $67.65 | 13,800 |
| 2026-10-19 | $65.58 | 24,000 |
| 2026-10-16 | $64.31 | 34,000 |
| 2026-10-15 | $67.01 | 23,200 |
| 2026-10-14 | $65.91 | 25,100 |
| 2026-10-13 | $65.34 | 53,600 |
| 2026-10-12 | $66.64 | 55,400 |
| 2026-10-09 | $68.75 | 24,300 |
| 2026-10-08 | $65.83 | 24,700 |
| 2026-10-07 | $66.85 | 131,300 |
| 2026-10-06 | $67.60 | 85,700 |
| 2026-10-05 | $72.30 | 61,800 |
| 2026-10-02 | $69.62 | 16,800 |
| 2026-10-01 | $68.78 | 45,600 |
| 2026-09-30 | $70.48 | 16,100 |
| 2026-09-29 | $70.35 | 18,600 |
| 2026-09-28 | $70.30 | 90,500 |
About Global X Genomics & Biotechnology ETF
The fund invests at least 80% of its total assets in the securities of the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are positioned to benefit from further advances in the field of genomic science and biotechnology, as well as applications thereof (collectively, "Genomics & Biotechnology Companies"), as defined by Solactive AG, the provider of the underlying index. The fund is non-diversified.
đ° Latest News
No news articles available at the moment. Check back later for updates on GNOM.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.